Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK

Mundipharma

Status: Completed

Conditions: Chronic Pain

Study type: Observational

Funder types: Industry

Identifiers

NCT01225861

241437

Details and patient eligibility

About

The primary objective of the study is the descriptive analysis of incidence & severity of side effects & reasons for discontinuation of the treatment of chronic pain with transdermal analgesic Buprenorphine patches.

Full description

750 patients that are treated with transdermal Buprenorphine patches for chronic pain will be included in the study. About 20% of patients are aimed to be patch-naive, ie have received their first prescription of transdermal analgesic patches within 1 month before inclusion in this observational study. Furthermore the study should not include more than 25% of cancer patients that are treated for chronic pain in order to ensure an appropriate mix of patient population.

Enrollment: 750 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Patient age > 18
• Patient is treated with transdermal Buprenorphine
• The patient is able to answer the patient's survey & has an estimated overall survival of minimum 6 months
• The patient gives his/her informed, written consent to participate in the study

Exclusion Criteria

• Patient Age < 18
• Patient has less than 6 months survival expectancy
• Patient is unable to answer the patient survey for whatever reason in any feasible form